Exploring vitamin D3 as immunomodulator

Inspire your next pharma innovation with vitamin D3

The COVID-19 public health crisis has strongly accelerated research and innovation in the pharma market, highlighting the potential role of vitamin APIs in patient health. In particular, the fast-evolving science behind vitamin D3 – or cholecalciferol – has received increasing interest amongst pharmaceutical manufacturers looking to innovate in the immunity market.

A growing bank of research reveals that vitamin D3 may provide significant therapeutic benefits in a number of immune-related diseases, including COVID-19 infection. Additionally, vitamin D levels are reportedly lower in critically ill patients which can increase the risk of adverse clinical outcomes, disease severity and mortality. With this in mind, researchers are exploring the promising role of vitamin D3 as an adjuvant therapy in these individuals.

Our new whitepaper provides a scientific overview of the clinical evidence supporting the role of vitamin D3 as an immunomodulator, including its protective effect in immune-related diseases. Download the whitepaper now to inspire the development of purpose-led pharmaceuticals that will support patients’ quality of life.

Quick Links


Request samples, place orders and view product documentation


Download the latest copy of our Solutions Catalogue

Contact Us

We’re more than a partner. We’re a competitive edge.


The latest in vitamin and lipid research and industry developments


Academic studies and the latest science in educational modules


Videos exploring the growing role of vitamin APIs and lipid API intermediates